FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022752808> ?p ?o ?g. }

• W2022752808 endingPage "1407" @default.
• W2022752808 startingPage "1398" @default.
• W2022752808 abstract "Balsalazide is a new innovative, mesalamine-containing prodrug that is activated by bacteria in the colon. Balsalazide has been shown previously to be well tolerated and effective in the treatment of acute ulcerative colitis. The aim of this study was to determine the dose-response of balsalazide for efficacy and safety in active, mild-to-moderate ulcerative colitis and to compare this profile with that of mesalamine, pH-dependent, delayed-release tablets.A multicenter, randomized, active control, double-blind, double-dummy, dose-response, parallel-group study was performed comparing balsalazide (6.75 g daily), balsalazide (2.25 g daily), and mesalamine (2.4 g daily), administered for 8 wk to 154 patients with active, mild-to-moderate ulcerative colitis as verified by sigmoidoscopy.Eight weeks of treatment with 6.75 g of balsalazide daily provided significantly greater improvement than did balsalazide (2.25 g daily) in rectal bleeding (64.7% [6.75-g balsalazide] vs 32.4% [2.25-g balsalazide], p < 0.006), stool frequency (58.8% vs 29.4%, p < 0.006), sigmoidoscopic score (78.9% vs 52.5%, p < 0.015), and Physician's Global Assessment (73.7% vs 51.3%, p < 0.03). The efficacy of balsalazide showed a significantly more rapid onset of action than that of mesalamine (2.4 g daily) (2-wk sigmoidocopic score improvement, 54.7% [6.75-g balsalazide] vs 29.4% [2.4-g mesalamine], p = 0.006) with numerically greater improvement at 8 wk in five of seven measured signs and symptoms. Balsalazide (6.75 g daily) was well tolerated, and the safety profile did not differ significantly from that of balsalazide (2.25 g daily) or mesalamine.Eight weeks of treatment with balsalazide (6.75 g daily) is significantly more effective than balsalazide (2.25 g daily) and more rapid in onset than mesalamine (2.4 g daily) in improving signs and symptoms of acute ulcerative colitis. Balsalazide (6.75 g daily) is well tolerated, and the safety profile does not differ from that of balsalazide (2.25 g daily) and mesalamine (2.4 g daily)." @default.
• W2022752808 created "2016-06-24" @default.
• W2022752808 creator A5000642535 @default.
• W2022752808 creator A5005945832 @default.
• W2022752808 creator A5009322004 @default.
• W2022752808 creator A5017813712 @default.
• W2022752808 creator A5028658450 @default.
• W2022752808 creator A5038866640 @default.
• W2022752808 creator A5042501051 @default.
• W2022752808 creator A5075215868 @default.
• W2022752808 date "2002-06-01" @default.
• W2022752808 modified "2023-10-06" @default.
• W2022752808 title "A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis1" @default.
• W2022752808 cites W1964958755 @default.
• W2022752808 cites W1973960461 @default.
• W2022752808 cites W1984725180 @default.
• W2022752808 cites W2009300212 @default.
• W2022752808 cites W2024513902 @default.
• W2022752808 cites W2027122987 @default.
• W2022752808 cites W2028851330 @default.
• W2022752808 cites W2032900832 @default.
• W2022752808 cites W2033317644 @default.
• W2022752808 cites W2053380345 @default.
• W2022752808 cites W2106863712 @default.
• W2022752808 cites W2123830992 @default.
• W2022752808 cites W2129694146 @default.
• W2022752808 cites W2140637127 @default.
• W2022752808 cites W2161667176 @default.
• W2022752808 cites W2415775034 @default.
• W2022752808 cites W3189729639 @default.
• W2022752808 doi "https://doi.org/10.1111/j.1572-0241.2002.05781.x" @default.
• W2022752808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12094857" @default.
• W2022752808 hasPublicationYear "2002" @default.
• W2022752808 type Work @default.
• W2022752808 sameAs 2022752808 @default.
• W2022752808 citedByCount "68" @default.
• W2022752808 countsByYear W20227528082012 @default.
• W2022752808 countsByYear W20227528082013 @default.
• W2022752808 countsByYear W20227528082014 @default.
• W2022752808 countsByYear W20227528082015 @default.
• W2022752808 countsByYear W20227528082016 @default.
• W2022752808 countsByYear W20227528082017 @default.
• W2022752808 countsByYear W20227528082018 @default.
• W2022752808 countsByYear W20227528082019 @default.
• W2022752808 countsByYear W20227528082020 @default.
• W2022752808 countsByYear W20227528082022 @default.
• W2022752808 crossrefType "journal-article" @default.
• W2022752808 hasAuthorship W2022752808A5000642535 @default.
• W2022752808 hasAuthorship W2022752808A5005945832 @default.
• W2022752808 hasAuthorship W2022752808A5009322004 @default.
• W2022752808 hasAuthorship W2022752808A5017813712 @default.
• W2022752808 hasAuthorship W2022752808A5028658450 @default.
• W2022752808 hasAuthorship W2022752808A5038866640 @default.
• W2022752808 hasAuthorship W2022752808A5042501051 @default.
• W2022752808 hasAuthorship W2022752808A5075215868 @default.
• W2022752808 hasConcept C121608353 @default.
• W2022752808 hasConcept C126322002 @default.
• W2022752808 hasConcept C2778435480 @default.
• W2022752808 hasConcept C2779134260 @default.
• W2022752808 hasConcept C2779896975 @default.
• W2022752808 hasConcept C2780479503 @default.
• W2022752808 hasConcept C526805850 @default.
• W2022752808 hasConcept C71924100 @default.
• W2022752808 hasConcept C90924648 @default.
• W2022752808 hasConceptScore W2022752808C121608353 @default.
• W2022752808 hasConceptScore W2022752808C126322002 @default.
• W2022752808 hasConceptScore W2022752808C2778435480 @default.
• W2022752808 hasConceptScore W2022752808C2779134260 @default.
• W2022752808 hasConceptScore W2022752808C2779896975 @default.
• W2022752808 hasConceptScore W2022752808C2780479503 @default.
• W2022752808 hasConceptScore W2022752808C526805850 @default.
• W2022752808 hasConceptScore W2022752808C71924100 @default.
• W2022752808 hasConceptScore W2022752808C90924648 @default.
• W2022752808 hasIssue "6" @default.
• W2022752808 hasLocation W20227528081 @default.
• W2022752808 hasLocation W20227528082 @default.
• W2022752808 hasOpenAccess W2022752808 @default.
• W2022752808 hasPrimaryLocation W20227528081 @default.
• W2022752808 hasRelatedWork W2086156447 @default.
• W2022752808 hasRelatedWork W2133658657 @default.
• W2022752808 hasRelatedWork W2404259405 @default.
• W2022752808 hasRelatedWork W2464962541 @default.
• W2022752808 hasRelatedWork W2475104063 @default.
• W2022752808 hasRelatedWork W2896381073 @default.
• W2022752808 hasRelatedWork W2999527238 @default.
• W2022752808 hasRelatedWork W3014832808 @default.
• W2022752808 hasRelatedWork W4210249856 @default.
• W2022752808 hasRelatedWork W4382881471 @default.
• W2022752808 hasVolume "97" @default.
• W2022752808 isParatext "false" @default.
• W2022752808 isRetracted "false" @default.
• W2022752808 magId "2022752808" @default.
• W2022752808 workType "article" @default.